TAK-700 – No competitive edge against Zytiga Generics; while in early setting competition is also heating up! In the recent past, treatment paradigm of metastatic prostate cancer (mPC) has witnessed
Merck -Suvorexant delayed but no additional studies required is a sigh of relief
Date:
2015-07
MORE PUBLICATIONS
Merck -Suvorexant delayed but no additional studies required is a sigh of relief
US$ 90 2015-07 Pages: 1Categories
- Automotive
- Bearings
- Business Services
- Chemicals and Materials
- Coatings
- Company Profiles
- Consumer Goods
- Defense
- Electronics
- Energy
- Financial Services
- Food & Beverages
- Manufacturing & Construction
- Medical Devices
- Pharmaceuticals and Healthcare
- Public Sector
- Resins
- Technology
- Telecommunications and Wireless
- Vacuum Products
Popular Articles
Sorry. No data so far.
